Literature DB >> 23283606

Even 'safe' medications need to be administered with care.

Nancy Lutwak1, Mary Ann Howland, Rosemarie Gambetta, Curt Dill.   

Abstract

A 60-year-old man with a history of hepatic cirrhosis and cardiomyopathy underwent transoesophageal echocardiogram. He received mild sedation and topical lidocaine. During the recovery period the patient developed ataxia and diplopia for about 30 mins, a result of lidocaine toxicity. The patient was administered a commonly used local anaesthetic, a combination of 2% viscous lidocaine, 4% lidocaine gargle and 5% lidocaine ointment topically to the oropharnyx. The total dose was at least 280 mg. Oral lidocaine undergoes extensive first pass metabolism and its clearance is quite dependent on rates of liver blood flow as well as other factors. The patient's central nervous system symptoms were mild and transient but remind us that to avoid adverse side effects, orally administered drugs with fairly high hepatic extraction ratio given to patients with chronic liver disease need to be given in reduced dosages. Even 'Safe' medications need to be carefully administered.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23283606      PMCID: PMC3604254          DOI: 10.1136/bcr-2012-006204

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  Molecular modeling of local anesthetic drug binding by voltage-gated sodium channels.

Authors:  Gregory M Lipkind; Harry A Fozzard
Journal:  Mol Pharmacol       Date:  2005-09-20       Impact factor: 4.436

2.  Systemic absorption and toxicity from topically administered lidocaine during transesophageal echocardiography.

Authors:  S C Sharma; P R Rama; G L Miller; E B Coccio; L J Coulter
Journal:  J Am Soc Echocardiogr       Date:  1996 Sep-Oct       Impact factor: 5.251

Review 3.  Alternative routes of drug administration--advantages and disadvantages (subject review). American Academy of Pediatrics. Committee on Drugs.

Authors: 
Journal:  Pediatrics       Date:  1997-07       Impact factor: 7.124

4.  Hepatic lidocaine metabolism in chronic hepatitis C virus hepatitis with or without steatosis.

Authors:  G Taliani; F Duca; R Lecce; D Livoli; C Pasquazzi; C De Bac
Journal:  Hepatology       Date:  1995-06       Impact factor: 17.425

Review 5.  The MEGX test: a tool for the real-time assessment of hepatic function.

Authors:  M Oellerich; V W Armstrong
Journal:  Ther Drug Monit       Date:  2001-04       Impact factor: 3.681

6.  Deaths related to liposuction.

Authors:  R B Rao; S F Ely; R S Hoffman
Journal:  N Engl J Med       Date:  1999-05-13       Impact factor: 91.245

7.  Effects of intravenous lipid as a source of energy in parenteral nutrition associated hepatic dysfunction and lidocaine elimination: a study using isolated rat liver perfusion.

Authors:  N Zaman; Y K Tam; L D Jewell; R T Coutts
Journal:  Biopharm Drug Dispos       Date:  1997-12       Impact factor: 1.627

Review 8.  Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Authors:  Roger K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953

9.  Transitory ataxia related to topically administered lidocaine.

Authors:  Pascal Perney; François Blanc; Georges Mourad; Jean-Pierre Blayac; Dominique Hillaire-Buys
Journal:  Ann Pharmacother       Date:  2004-03-23       Impact factor: 3.154

10.  Role of cytochrome P450 in drug interactions.

Authors:  Zakia Bibi
Journal:  Nutr Metab (Lond)       Date:  2008-10-18       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.